Preclinical Cushing's syndrome in diabetes mellitus of Japan

Preclinical Cushing's syndrome in diabetes mellitus of Japan - PCUJ study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-C000000453

Enrollment

1000

Registered

2006-08-01

Start date

2006-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preclinical Cushing&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient or admitted patients with type 2 diabetes according to the criteria of the Japan Diabetes Society are recruited to the study.

Exclusion criteria

Exclusion criteria: 1. Patients with overt signs or symptoms of Cushing's syndrome, including moon face, buffalo hump, central obesity, striae cutis, etc. 2. Patients under the treatment of glucocorticoids or with the history of long-term glucocorticoid therapy over six months. 3. Patients with type 1 diabetes mellitus, gestational diabetes mellitus, and other secondary diabetes. 4. Patients with conditions or illness described below; 4-1. Conditions or illness with possible alteration of ACTH-cortisol secretion, including -chronic alcoholism -sleep apnea syndrome -poorly controlled diabetes(HbA1c>=10.0%) -irregular life style with altered sleep-awake cycle 4-2. Unstable and/or severe illness considered to be not suitable for the study, including -coronary heart disease(myocardial infarction, angina pectoris) -arrhythmia -severe valvular heart diseases -hypertrophic cardiomyopathy -congestive heart failure -cerebrovascular disease(cerebral apoplexy, transient ischemic attack) -acute or chronic renal failure(serum Cr>=3mg/dl) -acute or chronic liver disease (moderate to severe) -asymptomatic hypoglycemia -active stage of peptic ulcer 5. Patients under the treatment of drugs such as phenobarbital, rifampicin, carbamazepine, phenytoin, ephedrine, and macrolide antibiotics, which can alter the effect of dexamethasone. 6. Other various conditions if the attending physician make decision not suitable for the study.

Design outcomes

Primary

Measure	Time frame
To elucidate the prevalence of preclinical Cushing's syndrome in Japanese Type 2 diabetic patients	—

Secondary

Measure	Time frame
To elucidate the prognosis of the preclinical Cushing's syndrome and its interrelationship with obesity, hypertension, and hyperlipidemia	—

Countries

Japan

Contacts

Public ContactMitsuhide Naruse

National Hospital Organization, Kyoto Medical Center Department of Endocrinology, Clinical Research Institute for Endocrine and Metabolic Diseases

mnaruse@kyotolan.hosp.go.jp075-641-9164

Outcome results